DevansuTewariMD
Obstetrics & Gynecology • Anaheim, CAGynecologic Oncology
Director, Gynecologic Oncology SCPMG-Orange County
Dr. Tewari is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
441 N Lakeview Ave
Anaheim, CA 92807Phone+1 714-279-4103Fax+1 949-932-6393
Education & Training
University of California (Irvine)Residency, Obstetrics and Gynecology, 1997 - 2001
University of California, Irvine, School of MedicineClass of 1997
Certifications & Licensure
OR State Medical License 2006 - Present
CA State Medical License 1999 - 2027
HI State Medical License 2012 - 2026- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
- Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Clinical Trials
- Improving Tumor Oxygenation in Cervical Cancer Start of enrollment: 2004 Jul 01
- Comparing Strategies for Implementing Primary HPV Screening Start of enrollment: 2019 Mar 01
Publications & Presentations
PubMed
- 95 citationsImpact of COVID-19 on Cervical Cancer Screening Rates Among Women Aged 21-65 Years in a Large Integrated Health Care System - Southern California, January 1-September ...Maureen J. Miller, Lanfang Xu, Jin Qin, Erin E. Hahn, Quyen Ngo-Metzger
MMWR. Morbidity and Mortality Weekly Report. 2021-01-29 - 12 citationsPrimary invasive vaginal cancer in the setting of the Mayer-Rokitansky-Kuster-Hauser syndrome.Devansu Tewari, Michael T. McHale, Jeffrey V. Kuo, Bradley J. Monk, Robert A. Burger
Gynecologic Oncology. 2002-05-01 - 69 citationsGemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.Rodney P. Rocconi, Elizabeth A. Grosen, Sharad A. Ghamande, John K. Chan, Minal A. Barve
The Lancet. Oncology. 2020-12-01
Press Mentions
Kaiser Permanente Study Finds a More Effective Way to Test for HPVOctober 20th, 2017
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
